Department of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Korean J Radiol. 2022 Jul;23(7):697-719. doi: 10.3348/kjr.2021.0593. Epub 2022 May 9.
Gadoxetate magnetic resonance imaging (MRI) is widely used in clinical practice for liver imaging. For optimal use, we must understand both its advantages and limitations. This article is the outcome of an online advisory board meeting and subsequent discussions by a multidisciplinary group of experts on liver diseases across the Asia-Pacific region, first held on September 28, 2020. Here, we review the technical considerations for the use of gadoxetate, its current role in the management of patients with hepatocellular carcinoma (HCC), and its relevance in consensus guidelines for HCC imaging diagnosis. In the latter part of this review, we examine recent evidence evaluating the impact of gadoxetate on clinical outcomes on a continuum from diagnosis to treatment decision-making and follow-up. In conclusion, we outline the potential future roles of gadoxetate MRI based on an evolving understanding of the clinical utility of this contrast agent in the management of patients at risk of, or with, HCC.
钆塞酸二钠磁共振成像（MRI）广泛应用于临床肝脏成像。为了实现最佳应用，我们必须了解其优势和局限性。本文是亚太地区多学科肝病专家在线咨询委员会会议的成果，以及随后的讨论，该会议于 2020 年 9 月 28 日首次举行。在这里，我们回顾了使用钆塞酸的技术考虑因素、其在肝细胞癌（HCC）患者管理中的当前作用，以及在 HCC 成像诊断共识指南中的相关性。在本综述的后半部分，我们研究了最近的证据，评估了从诊断到治疗决策和随访连续体上钆塞酸对临床结果的影响。总之，我们根据对这种对比剂在管理有或患有 HCC 风险的患者中的临床应用的不断理解，概述了钆塞酸 MRI 的潜在未来作用。
